Evaluation of memantine for neuroprotection in dementia

Bibliography

• JAIN KK: Neuroprotection in disorders of CNS. Jain PharmaBiotech Publications. Basel, Switzerland, (2000).
   Google Scholar
• ••An in-depth review of mechanisms of neuroprotection andmethods for protecting against brain damage in various disorders of the central nervous system such as stroke, traumatic brain injury and neurodegenerative disorders. Pathophysiology of these disorders is discussed as a basis for neuroprotection. Markets for neuroprotectives and companies developing them are also described.
   Google Scholar
• GERZON K, KRUMKALNS EV, BRINDLE RL et al.: The adamantyl group in medicinal agents. I. Hypoglycemic N-arylsulfonyl-N'-adamantylureas. J. Med. Chem. (1963) 6:760–763.
   PubMed Web of Science ®Google Scholar
• WESEMAN W, SONTAG KH, MAJ J: On the pharmacody-namics and pharmacokinetics of memantine. Arzneim Forsch Drug Res. (1983) 33:1122–1134.
   PubMedGoogle Scholar
• FLEISCHHACKER WW, BUCHGEHER A, SCHUBERT H: Memantine in the treatment of senile dementia of the Alzheimer type. Prog. Neuropsychopharmacol. Biol. Psychiatry (1986) 10:87–93.
   PubMed Web of Science ®Google Scholar
• KORNHUBER J, BORMANN J, HOBERS M et al.: Memantine displaces MK-801 at therapeutic concen-trations in postmortem human frontal cortex. Eur. J. Pharmacol. (1989) 166:589–590.
   PubMed Web of Science ®Google Scholar
• PARSONS CG, DANYSZ W, QUACK G: Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology (1999) 38:735–767.
   PubMed Web of Science ®Google Scholar
• ••Most thorough review of the pharmacology of memantine.
   Google Scholar
• SOBOLEVSKY A, KOSHELEV SG, KHODOROV BI: Interac-tion of memantine and amantadine with agonist-unbound NMDA receptor channels in acutely isolated rat hippocampal neurons. J. Physiol. (1998) 512:47–60.
   PubMed Web of Science ®Google Scholar
• BRESINK I, BENKE TA, COLLETT VJ et al.: Effects ofmemantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br. J. Pharmacol. (1996) 119:195–204.
   PubMed Web of Science ®Google Scholar
• PARSONS CG, QUACK G, BRESINK I et al.: Comparison ofthe potency kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activityin vivo. Neuropharmacology(1995)34:1239–1258.
   PubMed Web of Science ®Google Scholar
• BLANPIED TA, BOECKMAN FA, AIZENMAN E et al.: Trapping channel block of NMDA-activated responses by amantadine and memantine. J. Neurophysiol. (1997) 77:309–323.
   PubMed Web of Science ®Google Scholar
• KEILHOFF G, WOLF: Memantine prevents quinolinic acid-induced hippocampal damage. Eur. J. Pharmacol. (1992) 219:451–454.
   PubMed Web of Science ®Google Scholar
• SCHULZ JB, MATHEWS RT, HENSHAW DR et al.: Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience (1996) 71:1043–1048.
   PubMed Web of Science ®Google Scholar
• STIEG PE, SATHI S, WARACH S et al.: Neuroprotection bythe NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. Eur.J. Pharmacol. (1999) 375:115–120.
   PubMed Web of Science ®Google Scholar
• DOGAN A, ERAS MA, RAO VL et al.: Protective effects ofmemantine against ischemia-reperfusion injury in spontaneously hypertensive rats. Acta Neurochir. (Wien) (1999) 141:1107–1113.
   PubMed Web of Science ®Google Scholar
• MOBIUS HJ: Pharmacologic rationale for memantine inchronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Dis. Assoc. Disord. (1999) 13\(Suppl. 3):S172–5178.
   Google Scholar
• HOLDEN CP, HAUGHEY NJ, NATH A et al.: Role of Na+/H+ exchangers, excitatory amino acid receptors and voltage-operated Ca2+ channels in human immunodeficiency virus Type 1 gp120-mediated increases in intracellular Ca2+ in human neurons and asWocytes. Neuroscience (1999) 91:1369–1378.
   PubMed Web of Science ®Google Scholar
• NATH A, HAUGHEY NJ, JONES M et al.: Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann. Neurol. (2000) 47:186–194.
   PubMed Web of Science ®Google Scholar
• KORNHUBER J, QUACK G: Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate receptor antagonist memantine in man. Neurosci. Lett. (1995) 195:137–139.
   PubMed Web of Science ®Google Scholar
• DIMPFEL W: Effects of memantine on synaptic transmission in the hippocampus in vitro. Arzneimit-telforschung (1995) 45:1–5.
   PubMed Web of Science ®Google Scholar
• PELLEGRINI JW, LIPTON SA: Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann. Neurol. (1993) 33:403–407.
   PubMed Web of Science ®Google Scholar
• MULLER WE, SCHRODER HC, USHIJIMA H et al.: Gp120 of HIV-1 induces apoptosis in rat cortical cell cultures: prevention by memantine. Eur. J. Pharmacol. (1992) 226:209–214.
   PubMed Web of Science ®Google Scholar
• BERGER W, DECKERT J, HARTMANN J et al Memantineinhibits [3H]MK-801 binding to human hippocampal NMDA receptors. Neuroreport (1994) 5:1237–1240.
   PubMed Web of Science ®Google Scholar
• FRANKIEWICZ T, PARSONS CG: Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Neurophar-macology (1999) 38:1253–1259.
   PubMed Web of Science ®Google Scholar
• BARNES CA, DANYSZ W, PARSONS CG: Effects of theuncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur. J. Neurosci. (1996) 8:565–571.
   PubMed Web of Science ®Google Scholar
• ZAJACZKOWSKI W, QUACK G, DANYSZ W: Infusion of (+)-MK-801 and memantine- contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur. J. Neurosci. (1996) 296:239–246.
   Web of Science ®Google Scholar
• ZAJACZKOWSKI W, FRANKIWICZ T, PARSONS CG et al.: Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology (1997) 36:961–971.
   PubMed Web of Science ®Google Scholar
• WENK GL, ZAJACZKOWSKI, DANYSZ W: Neuroprotec-tion of acetykholinergic basal forebrain neurons by memantine and neurokinin B. Behav. Brain Res. (1997) 83:129–133.
   PubMed Web of Science ®Google Scholar
• MIGUEL-HIDALGO 41, ALVAREZ XA, QUACK G et al.: Protection by memantine against AO (1–40)-induced neurodegeneration in the CA1 subfield. Neurobiol. Aging (1998) 19\(Suppl. 45):5129 (Abstract).
   Google Scholar
• AMBROZI L, DANIELCZYK W: Treatment of impaired cerebral function in psychogeriatric patients with memantine- results of a Phase II double-blind study. Pharmacopsychiatry (1988) 21:144–146.
   PubMed Web of Science ®Google Scholar
• GORTELMEYER, ERBLER: Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelforschung (1992) 42:904–913.
   PubMed Web of Science ®Google Scholar
• DITZLER K: Efficacy and tolerability of memantine inpatients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung (1991) 41:773–780.
   Google Scholar
• PANTEV M, RITTER R, GORTELMEYER R: Clinical andbehavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Zeitschrift fur Gentopsychologie und-psychiatrie (1993) 6:103–117.
   Google Scholar
• WINBLAD B, PORITIS N: Memantine in severe dementia:results of the 9M-Best study (Benefit and efficacy in severely demented patients during treatment with memantine.) Int. J. Geriatr. Psychiatry (1999) 14:135–146
   PubMed Web of Science ®Google Scholar
• TOMITAKA S, HASHIMOTO K, NARITA N et al.: Memantine induces heat shock protein HSP 70 in the posterior cingulate cortex, retrosplenial cortex and dentate gyrus of the rat brain. Brain Res. (1996) 763:255–258.
   Web of Science ®Google Scholar
• WENK GL, QUACK G, MOEBIUS HJ, DANYSZ W: No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. (2000) 66(12):1079–1083.
   PubMed Web of Science ®Google Scholar